Evidence map›Paper›PMID 36126275›Full record

ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2022

A Cross-Sectional Study of the Prevalence of Anal Dysplasia among Women with High-Grade Cervical, Vaginal, and Vulvar Dysplasia or Cancer: The PANDA Study.

Samantha Batman, Craig A Messick, Andrea Milbourne, Ming Guo, Mark F Munsell, Joel Fokom-Domgue, Mila Salcedo, Ashish Deshmukh, Kristina R Dahlstrom, Mallory Ogburn and 9 more

Open access · greenAbstract read
In one paragraph

Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Trial
  2. Article
  3. Evidence for Anal Dysplasia Treatment.Clinics in colon and rectal surgery · 2026
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 5 institutions in 1 country.

Samantha BatmanThe University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-0250-2322
Craig A MessickThe University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-0714-5037
Andrea MilbourneThe University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-3578-4306
Ming GuoThe University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-6773-1145
Mark F MunsellThe University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-9654-4958
Joel Fokom-DomgueThe University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-4722-9262
Mila SalcedoThe University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-6375-0736
Ashish DeshmukhThe University of Texas Health Science Center, Houston, Texas.ORCID 0000-0001-8936-8108
Kristina R DahlstromBaylor College of Medicine, Houston, Texas.ORCID 0000-0002-8116-9558
Mallory OgburnThe University of Texas Rio Grande Valley, Edinburg, Texas.ORCID 0000-0002-5138-8856
Anthony PriceThe University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-8927-3384
Nicole D FlemingThe University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-1785-4072
Jolyn TaylorThe University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-1267-4371
Aaron ShaferThe University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-2565-0264
Lauren CobbThe University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-0778-7366
Keith SigelThe Mount Sinai Hospital, New York, New York.ORCID 0000-0002-4051-4861
Erich M SturgisBaylor College of Medicine, Houston, Texas.ORCID 0000-0002-1069-4822
Elizabeth Y ChiaoThe University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-5752-2916
Kathleen M SchmelerThe University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-9670-4189
The University of Texas MD Anderson Cancer Center · USBaylor College of Medicine · USMount Sinai Hospital · USThe University of Texas Health Science Center · USThe University of Texas Rio Grande Valley · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Training of Academic Gynecologic OncologistsT32CA101642 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI ANIL K SOOD, Kathleen Schmeler · 2005 to 2026
$9.2M
NCI NIH HHS P30 CA016672NCI NIH HHS T32 CA101642
6 · The paper itself

Abstract

backgroundHigh-risk human papillomavirus (HR-HPV) infection is a risk factor for anal cancer, yet no anal cancer screening guidelines exist for women with lower genital tract HPV-related disease. We sought to describe the prevalence of anal HR-HPV or cytologic abnormalities in such women.

methodsThis cross-sectional study was performed between October 2018 and December 2021. Inclusion criteria were ≥21 years of age and a prior diagnosis of high-grade dysplasia/cancer of the cervix, vagina, or vulva. Participants underwent anal cytology and anal/cervicovaginal HR-HPV testing. Women with abnormal anal cytology were referred for high-resolution anoscopy (HRA).

results324 evaluable women were enrolled. Primary diagnosis was high-grade dysplasia/cancer of the cervix (77%), vagina (9%), and vulva (14%). Anal HR-HPV was detected in 92 patients (28%) and included HPV-16 in 24 (26%), HPV-18 in 6 (7%), and other HR-HPV types in 72 (78%) patients. Anal cytology was abnormal in 70 patients (23%) and included atypical squamous cells of undetermined significance (80%), low-grade squamous intraepithelial lesion (9%), high-grade intraepithelial lesion (HSIL; 1%), and atypical squamous cells-cannot rule out HSIL (10%). Of these patients, 55 (79%) underwent HRA. Anal biopsies were performed in 14 patients: 2 patients had anal intraepithelial neoplasia (AIN) 2/3, 1 patient had AIN 1, and 11 patients had negative biopsies. Both patients with AIN 2/3 had a history of cervical dysplasia.

conclusionsOur results suggest an elevated risk of anal HR-HPV infection and cytologic abnormalities in women with lower genital tract dysplasia/cancer. IMPACT: These results add to the growing body of evidence suggesting the need for evaluation of screening methods for anal dysplasia/cancer in this patient population to inform evidence-based screening recommendations.

Indexed as

Anus DiseasesAnus NeoplasmsCarcinoma in SituPapillomavirus InfectionsSquamous Intraepithelial LesionsUterine Cervical NeoplasmsVulvar NeoplasmsCross-Sectional StudiesFemaleHumansPapillomaviridaePrevalenceVagina

Identifiers

PMID36126275
PMCPMC9729427
OpenAlexW4296784530

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.